During melanoma progression, tumour cells show increased adhesiveness to the vascular wall, invade the extracellular matrix (ECM) and frequently form functional channels similar to vascular vessels (vasculogenic mimicry). These properties are mainly mediated by the interaction of integrins with ECM components. Since we had previously identified neuropilin 1 (NRP-1), a coreceptor of vascular endothelial growth factor A (VEGF-A), as an important determinant of melanoma aggressiveness, aims of this study were to identify the specific integrins involved in the highly invasive phenotype of NRP-1 expressing cells and to investigate their role as targets to counteract melanoma progression. Melanoma aggressiveness was evaluated in vitro as cell ability to migrate through an ECM layer and to form tubule-like structures using transfected cells. Integrins relevant to these processes were identified using specific blocking antibodies. The avb5 integrin was found to be responsible for about 80% of the capability of NRP-1 expressing cells to adhere on vitronectin. In these cells avb5 expression level was twice higher than in low-invasive control cells and contributed to the ability of melanoma cells to form tubule-like structures on matrigel. Cilengitide, a potent inhibitor of am integrins activation, reduced ECM invasion, vasculogenic mimicry and secretion of VEGF-A and metalloproteinase 9 by melanoma cells. In conclusion, we demonstrated that amb5 integrin is involved in the highly aggressive phenotype of melanoma cells expressing NRP-1. Moreover, we identified a novel mechanism that contributes to the antimelanoma activity of the av integrin inhibitor cilengitide based on the inhibition of vasculogenic mimicry.
During disease progression, cutaneous malignant melanoma acquires a rich vascular network and increased ability to adhere to the vascular wall, which promotes the transition from the radial to the vertical growth phase. 1 The neovascularisation process is sustained by the secretion of various angiogenic cytokines [i.e., vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2, placental growth factor 1 and -2, interleukin 8 and transforming growth factor 1], integrin overexpression and release of high amounts of metalloproteinases (MMPs). 2, 3 Highly malignant cells, because of their ability to dedifferentiate and acquire characteristics of other cell types, form de novo vascular networks (vasculogenic mimicry), the presence of which predicts poor prognosis in melanoma patients. 4 This mechanism, that can contribute to new vessel formation and favour tumour growth and invasion, has been extensively studied utilizing melanoma cell lines, although it is also observed in a variety of other tumour types, including carcinomas, sarcomas, glioblastoma and astrocytoma. 4 Integrins are heterodimeric transmembrane glycoproteins essential for tumour progression that promote processes such as cell adhesion and migration. In cells that adhere to the extracellular matrix (ECM), integrins clusterize at the cell attachment sites, called focal adhesions, promoting the reorganization of the intracellular actin cytoskeleton and stimulating the activity of signalling molecules [e.g., protein kinases such as Src, focal adhesion kinase (FAK), extracellular signalrelated kinase (ERK1/2), protein kinase C (PKC)]. 5, 6 Besides allowing mechanical adhesive interactions, focal adhesions also permit tumour cells to sense the extracellular environment, responding through the activation of intracellular signalling pathways that trigger cell survival, proliferation or migration events. 7 Therefore, changes in integrin expression or integrin-mediated functions and signals deriving from the binding to specific ligands, influence the ability of melanoma cells to interact with the extracellular environment and favour metastatic progression by promoting a switch from a proliferative to an invasive phenotype. 8 Thus, integrins represent suitable targets of therapeutic strategies to inhibit the metastatic disease. In this regard, cilengitide, a cyclic arginine-glycine-aspartic acid containing pentapeptide that potently blocks the activation of av integrins (e.g., amb3 and amb5 integrins), represents the most clinically advanced integrin-targeting therapeutics. In fact, cilengitide is currently under evaluation in a phase III study (in combination with radio-chemotherapy) for newly diagnosed glioblastoma and in phase II studies for other tumour types, including metastatic melanoma [9] [10] [11] (www.clinicaltrials.gov). However, cilengitide as single agent has shown minimal clinical efficacy in patients with metastatic melanoma, suggesting that the integrin inhibitor may prove more effective in combination therapies. 12 Indeed, preclinical studies had shown that cilengitide and the methylating agent temozolomide (TMZ), currently used for the therapy of metastatic melanoma, exerted synergistic antiproliferative effects against melanoma and endothelial cells in vitro and induced a statistically significant reduction of in vivo melanoma growth, as compared to treatment with TMZ alone. 13 In this context, a better knowledge of the molecular mechanisms by which cilengitide affects melanoma cell growth and invasion might help to potentiate its anticancer activity by combination therapies.
To identify the specific integrins activated in highly aggressive melanomas that might be targeted for the treatment of the metastatic disease, we used a cellular model represented by different clones of the human melanoma cell line M14 14 : the M14C2/MK18 clone, expressing the VEGF-A receptor 2 (VEGFR-2) and the coreceptor neuropilin 1 (NRP-1), and the M14-N clone, expressing only NRP-1. 15, 16 M14C2/MK18 and M14-N clones display a highly invasive phenotype, demonstrated by their ability to migrate through an extracellular basement matrix. Studies utilizing these clones demonstrated that even though the simultaneous presence of both VEGFR-2 and NRP-1 potentiates VEGF-A secretion and the aggressiveness of melanoma cells, NRP-1 is by itself able to promote cell invasion. 15, 16 Actually, NRP-1 has been detected by immunostaining in tumour specimens of different tissue origin, including melanoma. 17, 18 Moreover, its expression levels have been found to directly correlate with the aggressiveness and invasive behaviour of prostate and gastrointestinal tumour cells. 19, 20 We therefore analysed the involvement of specific integrins in the invasion of ECM and in the vasculogenic mimicry by NRP-1 expressing melanoma cells. In addition, we investigated the potential activity of cilengitide as modulator of these processes.
Material and Methods

Reagents and cell lines
Cell culture media and reagents were purchased from Lonza (Basel, Switzerland), foetal bovine serum (FBS) was from Euroclone (Pero, Italy) and fatty acid-free bovine serum albumin (BSA) from Roche (Mannheim, Germany). VEGF-A and polyclonal antibodies used in ELISA assays (AF-293 and BAF-293), as well as the mouse immunoglobulin G1 (IgG1) control antibody (clone11711) used in the functional assays, were from R&D Systems (Abingdon, UK). The anti-avb3 (clone LM609), anti-avb5 (clone P1F6), anti-a2b1 (clone BHA 2.1) and anti-a5b1 (clone JBS5) monoclonal antibodies were from Chemicon International (Temecula, CA). Cilengitide was a kind gift from Merck (Merck KGaA, Darmstadt, Germany). The monoclonal antibody anti-NRP-1 (clone A12) was from Santa Cruz (Santa Cruz, CA). The concentrations of cilengitide used were as follows: 0.2-20 lg/ml in the assay of cell adhesion to vitronectin to evaluate the drug half maximal effective concentration (EC 50 ) and 20 lg/ml in all the other assays.
The origin and culture conditions of M14C2 subclones M14C2/C4, M14C2/MK18 and M14-N were previously described. 16, 21 The M14C2/MK18 clone is characterised by the activation of a VEGF-A/VEGF receptor 2 (VEGFR-2) autocrine loop, overexpression of the VEGF-A coreceptor NRP-1 and secretion of high levels of metalloproteinase 2 (MMP-2) 15 ; the M14-N clone expresses NRP-1 and secretes high levels of VEGF-A and MMP-2, but is defective in VEGFR-2 expression 16 ; the control M14C2/C4 clone is devoid of the expression of both VEGFR-2 and NRP-1 proteins and secretes lower amounts of VEGF-A and MMP-2.
15,16
The MW115 and MW266-4 cell lines were purchased from ATCC (Manassas, VA). Normal human fibroblasts were What's new? In melanoma, invasiveness is mediated by cell-adhesion molecules called integrins. A receptor called neuropilin-1 (NRP-1) also causes these tumors to become more aggressive. In this study, the authors identified specific av-integrins that are involved in the switching of melanoma cells that express NRP-1 to a metastatic phenotype. The study also identified a novel mechanism by which the peptide drug cilengitide may exert anti-melanoma activity: By inhibiting the activation of avb5 integrin, cilengitide blocks the formation of vascular networks by the tumor cells. This should, in turn, reduce the invasiveness of the tumors.
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kindly provided by the Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy.
Cell adhesion to ECM components
Cell adhesion was tested on 96-well plates previously coated with the commercial basement membrane matrix matrigel (20 mg/ml; BD Biosciences, Buccinasco, Italy), laminin (10 mg/ml, Sigma-Aldrich, Saint Louis, MO), Collagen I (10 mg/ml, Roche), Collagen IV (10 mg/ml, BD Biosciences), fibronectin (10 mg/ml, Sigma-Aldrich) or vitronectin (5 mg/ ml, Sigma-Aldrich) and blocked with 3% BSA. Cells were seeded into the wells (4 3 10 4 cells/well) and incubated at 37 C for 40 min. Nonadherent cells were, then, washed out and attached cells were fixed in ethanol and stained with crystal violet. The adhesion efficiency was determined by quantitative dye extraction and spectrophotometric measurement of the absorbance at 595 nm in a Microplate reader 3550-UV (Bio-Rad, Hercules, CA).
Chemotaxis and ECM cell invasion assays
In vitro invasion assays were performed using Boyden chambers equipped with 8-mm pore diameter polycarbonate filters (Nuclepore; Whatman Incorporated, Clifton, NJ), coated with 20 mg of matrigel.
14 Briefly, melanoma cells were collected from continuous cultures, washed, suspended in migration medium (1 mg/ml heparin/0.1% BSA in RPMI 1640), and loaded (2 3 10 5 cells) into the upper compartment of the Boyden chambers. Migration medium was also added to the lower compartment of the chambers. For each experimental condition, three Boyden chambers were set up. After incubation of the Boyden chambers at 37 C in a CO 2 incubator for 3 h, the filters were removed from the chambers and cells were fixed in ethanol for 5 min and stained in 0.5% crystal violet for 15 min. Nonmigrating cells were removed from the upper surface of the filter by wiping with a cotton swab and the migrated cells, attached to the lower surface of the filters, were counted under the microscope. Twelve highmagnification microscopic fields (3200 magnification), randomly selected on triplicate filters, were scored for each experimental condition. Where indicated, invasion assays were performed in the presence of antibodies directed against selected integrins or in the presence of cilengitide, after preincubation of the cells with these reagents for 30 min at room temperature, in a rotating wheel.
The chemotactic response of melanoma cells to different stimuli was analysed as described for the invasion assays, using polycarbonate filters coated with 5 mg/ml gelatin solution and allowing the cells to migrate for 18 h, as previously reported. 22 Flow cytometry analysis of integrin expression 
Evaluation of VEGF-A and MMP secretion
Semi-confluent melanoma cell cultures were incubated in 0.1% BSA/RPMI 1640 medium without FBS for 24 h. Culture supernatants were then collected, centrifuged at 600g for 10 min to remove cells in suspension, concentrated at least tenfold in Centriplus concentrators (Amicon, Beverly, MA) and frozen at 220 C till use. Cells were detached from the flasks with a solution of 1 mM EDTA in PBS and the total cell number/culture was recorded. Quantification of the amount of VEGF-A in the concentrated supernatants was performed using Maxisorp Nunc immunoplates (Nunc, Roskilde, Denmark) coated with goat anti-VEGF-A IgGs, as previously described. 23 The amount of MMP-2 and MMP-9 in the supernatants were determined using human Quantikine immunoassay kits (R&D Systems), whereas the amount of MMP-14 in supernatants and cell extracts was measured using an ELISA kit from MyBioSource (San Diego, CA), according to the manufacturer's directions. The activity of MMP-2 and MMP-9 was tested using QuickZyme activity assays (QuickZyme Biosciences, Leiden, The Netherlands).
Differentiation of melanoma cells in tubule-like structures
For the analysis of tubule-like structures on matrigel, the matrix was allowed to thaw overnight at 4 C and diluted 1:3 in serum-free RPMI 1640 medium. Diluted matrigel (100 ll) was layered onto 24-well plates that were then incubated at 37 C for 30 min, until matrigel solidification, as described. 24 Melanoma cells were suspended in complete culture medium (1 3 10 5 cells in 0.5 ml), dispensed onto the solidified matrix and incubated at 37 C in a 5% CO 2 environment. At the indicated times, the plates were photographed using a Leica inverted microscope and a Canon digital camera PowerShot G5. The formation of tubule-like structures was quantified by counting the number of cell intersections in ten different microscopic fields per group (350 magnification).
ITGB5 gene knockdown
M14-N cells were reverse transfected with either siRNA targeting the integrin b5 gene ITGB5 (ID 11201, Life Technologies, Carlsbad, CA) or nontargeting siRNA (Silencer Negative Control #1 siRNA, Life Technologies) to a final concentration of 20 nM, using lipofectamine RNAiMAX in OptiMEM serum-free medium (Life Technologies), according to the manufacturer's instructions. Cells were harvested 72 h after transfection and subjected to further analyses.
Cell proliferation assay
Cell proliferation was evaluated in 96-well plates using the te-
inner salt] from Promega (Madison, WI), as previously described. 22 
Statistics
Results are expressed as the arithmetic mean 6 standard deviation (SD) and significance of the differences was tested by unpaired, two-tailed Student's t-test; p values <0.05 (*), <0.01 (**) and <0.001 (***) were considered significant.
Results
Involvement of specific integrins in the adhesiveness and invasiveness of highly aggressive human melanoma cells expressing VEGFR-2 and NRP-1
We had previously reported the in vitro highly invasive phenotype and the in vivo aggressiveness of a cell clone originated from the human melanoma cell line M14 (M14C2/ MK18) that expresses VEGFR-2 and NRP-1 and secretes high levels of VEGF-A and MMP-2. 15 In order to investigate the involvement of specific integrins in the aggressiveness of these cells, we initially analysed cell adhesion to matrigel and to single ECM components, known to be ligands for specific integrins. The results demonstrated that M14C2/MK18 cells adhered more efficiently than the noninvasive control cells (the M14C2/C4 cell clone lacking both VEGFR-2 and NRP-1 expression) to matrigel (Fig. 1a) , Collagen IV, one of the main components of matrigel, or ECM components not present in matrigel, such as Collagen I and vitronectin (Fig. 1b) . Both melanoma cell clones adhered to fibronectin (not present in matrigel) to a similar extent, whereas none of them adhered to laminin, the other main component of matrigel (Fig. 1b) . The integrin contribution to the aggressive phenotype of M14C2/MK18 cells was confirmed by the finding of a constitutive activation of FAK, a kinase involved in the integrin-induced signal transduction pathway. In M14C2/C4 control cells the phosphorylated/active form of this kinase was, instead, detected only after induction of cell adhesion (Supporting information Fig. S1 ).
The integrins involved in the interaction of M14C2/MK18 cells with the different components of the ECM were then identified performing the adhesion assays in the presence of antibodies recognizing specific integrins known to bind particular ECM components. 25 Adhesion to Collagens I and IV was markedly inhibited by treatment of melanoma cells with blocking antibodies directed against a2b1 integrin (Fig. 1c) . The adhesion of these cells to vitronectin was strongly reduced by an antibody against the avb5 integrin, whereas it was only modestly affected by an antibody against avb3, the other main integrin interacting with vitronectin ( Fig. 1c) . Blocking antibodies against a5b1 integrin, the major fibronectin receptor, strongly interfered with the binding to this ECM component and to a minor extent to Collagen IV.
To test whether the differences in adhesion to Collagens I and IV and to vitronectin between M14C2/MK18 and M14C2/C4 clones were due to differences in the amount of a2b1 and avb5 active complexes on the cell surface, the integrin expression was evaluated by flow cytometry analysis ( Fig. 1d and Supporting information Fig. S2a) . The results showed that the expression of a2b1 and avb5 integrins in M14C2/MK18 cells was, respectively, fourfold and twofold higher than in the control cells. Conversely, the expression of avb3 expression in M14C2/MK18 was reduced by about a 40% (Fig. 1d) . These data might explain the relevance of avb5 in M14C2/K18 cell adhesion to vitronectin and the modest inhibitory effect of the anti-avb3 antibody on the adhesion to vitronectin.
We next investigated the specific role played by each of the above described integrins in the ability of M14C2/MK18 cells to adhere to and to migrate through a layer of matrigel as a measure of melanoma aggressiveness. Addition during the assays of specific anti-integrin antibodies demonstrated that inhibition of a2b1 integrin reduced cell adhesion by 50% (Fig.  1e) and cell invasion by 25% (Fig. 1f) . These results are consistent with the fact that Collagen IV is one of the principal matrigel components and are in agreement with the previously suggested involvement of a2b1 integrin in melanoma progression. 8, 26 The blockage of the avb3 or avb5 integrins, which are both vitronectin receptors, did not affect cell adhesion to matrigel, since vitronectin is not a matrigel component (Fig.  1e) . Nevertheless, the anti-avb3 or anti-avb5 integrin antibodies inhibited cell invasiveness through a matrigel monolayer by about 30% (Fig. 1f) , suggesting a role for these integrins in melanoma cell invasion by a mechanism different from cell adhesion to ECM components. Moreover, no changes in either adhesion or invasiveness of M14C2/MK18 cells were observed in the presence of anti-a5b1 integrin antibodies (Figs. 1e and 1f), indicating that this integrin is not directly involved in these melanoma properties.
Cilengitide inhibits invasiveness and vasculogenic mimicry of melanoma cells expressing VEGFR-2 and NRP-1
Based on the finding that antibodies against avb3 and avb5 integrins were able to inhibit the invasion of matrigel by M14C2/MK18 cells, we tested the ability of the av integrin inhibitor cilengitide to counteract melanoma cell invasiveness. Cilengitide inhibited adhesion of M14C2/MK18 cells to vitronectin in a dose-dependent manner, with an EC 50 of 6.66 6 1.77 mg/ml (Fig. 2a) , whereas this agent did not affect adhesion to fibronectin (used as negative control since it mainly interacts with the a5b1 integrin). The concentration of cilengitide causing the maximal inhibitory effect on adhesion to vitronectin (i.e., 20 mg/ml), strongly reduced the invasion of matrigel by M14C2/MK18 cells (Fig. 2b) without affecting cell viability (data not shown). Since cilengitide specifically interacts with the avb3 and avb5 integrins, our results confirmed the relevance of these integrins in melanoma invasiveness.
Previous studies have demonstrated a direct correlation between the avb3 and avb5 integrin expression and the formation by melanoma cells of tubule-like structures similar to those formed by endothelial cells under the same culture Cancer Cell Biology The effect of antibodies (3 lg/ml) that block specific integrins on M14C2/MK18 cell adhesion to matrigel was analysed as described in the legend to panels a and b.
(f) The influence of anti-integrin antibodies on melanoma cell invasion through matrigel was evaluated in Boyden chambers equipped with filters coated with 20 lg matrigel, in the presence of anti-integrin blocking antibodies. Cells (2 3 10 5 cells per chamber) were preincubated for 45 min at room temperature with 3 lg/ml of blocking antibodies that were maintained during the assay for 4 h at 37 C. CTRL Ab, control antibody (mouse IgG1 control). In all panels data represent the arithmetic mean values 6 SD of four to six independent determinations. conditions (vasculogenic mimicry). 27 We therefore evaluated the ability of M14C2/MK18 cells to arrange in tubular structures and the influence of cilengitide on this process. The results indicated that M14C2/MK18 cells, when cultured on matrigel, formed tubule-like structures (Fig. 2c) and that cilengitide significantly downmodulated this phenomenon (Figs. 2c and 2d ).
The expression of avb5 integrin is required for the inhibitory effect exerted by cilengitide on vasculogenic mimicry and invasiveness of melanoma cells expressing NRP-1 and not VEGFR-2
Since we had previously demonstrated that the aggressiveness of M14C2/MK18 cells is prevalently due to the presence of NRP-1, 15 the expression and functionality of avb5 and avb3 integrins were also analysed in a M14 cell subclone that expresses NRP-1 but not VEGFR-2 (M14-N cells). 16 M14-N cells showed higher adhesiveness to ECM components than NRP-1 negative control cells (M14C2/C4; Fig. 3a) . Nevertheless, the blockage of NRP-1 with an antibody that we previously reported to inhibit the matrigel invasion by both M14C2/MK18 and M14-N cell clones 15, 16 did not affect their adhesion to ECM components (Supporting information Fig. S2b ). M14-N cells had an almost identical pattern of integrin expression as M14C2/MK18 cells ( Fig. 3b and Supporting information Fig. S2a ) and were sensitive to the cilengitide inhibitory effect on adhesion to vitronectin (EC 50 of 2.06 6 0.01 mg/ml; Fig. 3c ). Treatment with cilengitide or with the anti-avb5 integrin antibody resulted in a similar inhibition (about 50%) of M14-N cell invasiveness (Fig. 3d) , but, unlike M14C2/MK18 cells, blockage of avb3 integrin with a specific antibody did not affect the invasiveness of M14-N cells (Fig. 3d versus Fig.  1f) . These data suggest a prevalent role of avb5 signalling in the invasive phenotype of melanoma cells expressing NRP-1 and lacking VEGFR-2 and indicate that NRP-1 does not directly interact with ECM components, but it is rather involved in melanoma cell adhesion and invasiveness through integrin activation (most likely the avb5 integrin).
M14-N cells were also able to form tubule-like structures on matrigel, and cilengitide treatment strongly reduced this property (Figs. 3e and 3f) . The effect of cilengitide did not depend on the matrigel components, since it was also observed when M14-N cells were allowed to form tubule-like structures in a Collagen I matrix (Supporting information Fig. S3 ). Moreover, cilengitide did not significantly inhibit adhesion to matrigel or Collagen I (Supporting information Fig. S4a ). Since cilengitide has been shown to cause tumour cell detachment and Cancer Cell Biology death, 28, 29 we have investigated whether this integrin inhibitor provoked similar effects in M14-N cells. However, in our melanoma model, cilengitide did not induce cell detachment or apoptosis (Supporting information Figs. S4b and S4c).
Further investigation on the relevance of avb3 and avb5 integrins on the vasculogenic mimicry phenotype of M14-N cells was performed by treating M14-N cells with specific neutralizing antibodies. The results demonstrated that avb5 integrin was required for the vasculogenic mimicry exhibited by NRP-1 positive melanoma cells, whereas avb3 integrin was found to be dispensable (Figs. 4a and 4b) .
The role of avb5 integrin in the aggressive properties of M14-N cells and in the effects of cilengitide was confirmed by gene silencing experiments (Figs. 4c and 4d and Supporting information Fig. S5 ). In fact, M14-N cells in which a strong reduction in avb5 integrin expression was obtained by b5 chain silencing, showed a reduced ability to invade matrigel and to form tubule-like structures and were not sensitive to the inhibitory effect of cilengitide (Figs. 4d-4f ).
Mechanisms involved in the inhibitory effects of cilengitide on M14-N cells
We had previously demonstrated that NRP-1 expressing melanoma cells produce higher levels of VEGF-A and MMP-2 as compared to NRP-1 negative syngeneic cells. 15, 16 Interestingly, it has been described that MMP-2 stimulates VEGF-A secretion by melanoma cells through the activation of avb5 integrin. 30 Therefore, the effect of cilengitide and the role of avb5 integrin on the secretion of both VEGF-A and MMP-2 by M14-N cells was also evaluated. Cilengitide and ITGB5 silencing significantly reduced the amounts of VEGF-A released in the supernatant by M14-N cells (Figs. 5a and 5b) . Treatment with cilengitide did not affect MMP-2 secretion or activity (Supporting information Figs. S6a and S6b), suggesting that in our model cilengitide might inhibit the MMP-mediated activation of avb5 integrin which is required for VEGF-A secretion by melanoma cells.
Other possible mechanisms of action of cilengitide were also investigated. In particular, the secretion of MMPs relevant to cell invasiveness (MMP-9 and MMP-14) was assayed. The levels of MMP-9 released by M14-N cells were higher than those produced by M14C2/C4 cells and treatment with cilengitide significantly reduced MMP-9 secretion and activity in M14-N supernatant (Figs. 5c and 5d ). The amount of MMP-14 secreted by M14-N cells was, instead, similar to that released by control melanoma cells (Supporting information Fig. S6c ). Since this MMP is known to process the MMP-2 that is bound to the cell membrane, 31 we also analysed the quantity of MMP-14 present in cell extracts. The MMP-14 found in cell extracts was 100-fold higher than in supernatants and significantly more expressed in M14-N cells than in M14C2/C4 cells (Supporting information Fig. S6d) . Moreover, cilengitide did not modulate the MMP-14 levels either in the supernatants or in the cell extracts (Supporting information Figs. S6c and S6d).
Since we and others have suggested a role for NRP-1 in endothelial or tumour cells independent of other VEGFRs, 16, 32, 33 we investigated whether cilengitide might modulate the response of M14-N cells to VEGF-A, using an in vitro chemotactic assay. Interestingly, cilengitide was found to inhibit the chemotactic response to VEGF-A, whereas it did not affect cell migration in response to human fibroblast conditioned medium (Fig. 5e) . However, cells exposed to the integrin inhibitor showed a round-shaped morphology (Supporting information Fig. S7) , likely due to a drug-mediated decrease in the phosphorylation of FAK, which is constitutively active in these cells (Fig. 5f) . Therefore, the mechanism by which cilengitide treatment affects invasiveness and vasculogenic mimicry of NRP-1 expressing melanoma cells seems to involve downregulation of VEGF-A production and an impaired response to this cytokine.
Effect of cilengitide on the invasiveness of melanoma cell lines expressing different levels of NRP-1
The influence of cilengitide on melanoma aggressiveness was also analysed in nontransfected cells, using two The number of cell intersections was counted in ten different microscopic fields for each of the experimental groups described in panel e. In all panels data represent the arithmetic mean values 6 SD of the results from three independent determinations.
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Ruffini et al. melanoma cell lines originated from the same patient and with elevated (WM115) or very low (WM266-4) NRP-1 expression (Fig. 6a) . WM115 cells were also characterized by a higher avb5 integrin expression (Fig. 6b and Supporting information Fig. S8 ), a lower proliferation rate (Fig. 6c) and a higher invasive capability (Fig. 6d) as compared to WM266-4 cells. Treatment with cilengitide resulted in a significant reduction of matrigel invasion only in the case of WM115 cells (Fig. 6d) . Moreover, WM115 cells were able to form tubule-like structures at a higher extent than WM266-4 cells, and this ability was strongly hampered by cilengitide (Figs. 6e and 6f) . It can be thus concluded that melanoma cells expressing avb5 integrin and high levels of NRP-1 display a more aggressive phenotype and that 
cilengitide is a good candidate to revert, at least in part, the invasive behaviour of these cells.
Discussion
Integrins represent highly attractive targets for anticancer therapy since they are critical intermediaries in a wide spectrum of tumour cell activities. However, modulation of the integrin functions is a complex issue. In fact, many different integrin heterodimers are expressed in a single cell and each of them can be involved in multiple intracellular signal transduction pathways. Therefore, the identification of the particular integrin that plays a dominant role in a specific tumour type or stage appears to be crucial for the design of new therapies targeting these ECM receptors. In the present study, we demonstrate for the first time that several of the characteristics contributing to the aggressive phenotype displayed by melanoma cells expressing NRP-1 require an active avb5 integrin and that avb3 integrin activation is needed when VEGFR-2 is coexpressed with NRP-1. Moreover, we show that cilengitide is able to inhibit the in vitro ECM invasion, tubule-like structures formation, production of and chemotactic response to VEGF-A and secretion of MMP-9 by melanoma cells expressing NRP-1.
Adhesion of NRP-1-positive melanoma cells to collagen, and more markedly to vitronectin, was increased as compared to NRP-1 negative cells. Vitronectin is an ECM component that plays a crucial role in many biological processes, such as cell migration, adhesion and angiogenesis, through the interaction with several members of the integrin family. [34] [35] [36] Analysing the integrins involved in the augmented adhesion of melanoma cells expressing VEGFR-2 and NRP-1 or NRP-1 only, our attention was focused on avb3 and avb5 integrins, two vitronectin receptors. Neutralizing antibodies against these integrins markedly inhibited in vitro melanoma cell invasiveness, even though vitronectin is not a component of matrigel (the commercial ECM utilized in the in vitro invasion assays). Therefore, mechanisms different from cell adhesion to ECM components (such as interaction of integrins with other membrane receptors and modulation of their signal transduction pathways) are likely to underlie the role of avb3 and avb5 integrins in melanoma invasiveness. Indeed, a direct physical interaction between VEGFR-2 and the b3 extracellular domain of avb3 integrin has been described. 37, 38 In endothelial cells, the b3 integrin subunit directly binds to NRP-1, limiting the interaction of this coreceptor with VEGFR-2 and modulating VEGF-A-mediated angiogenesis. 39 According to this study, in the presence of avb3 integrin, NRP-1 contributes minimally to VEGF-Ainduced angiogenic processes, whereas when the b3 integrin subunit is absent or low-expressed or its function is blocked, VEGF-A-mediated responses of endothelial cells become NRP-1-dependent. 39 Indeed, in M14C2/MK18 cells (expressing both NRP-1 and VEGFR-2) the level of avb3 integrin on the membrane surface was found to be reduced as compared with control cells (clone M14C2/C4, lacking NRP-1 and VEGFR-2 expression) and this might emphasize the contribution of NRP-1 to the aggressiveness of melanoma cells. Nevertheless, avb3 integrin still influences the invasiveness of M14C2/MK18 cells, even though it is expressed at low levels and is irrelevant for cell adhesion to vitronectin.
The M14-N melanoma cells, which express NRP-1 but not VEGFR-2, displayed characteristics almost identical to those of M14C2/MK18 cells (high in vitro invasiveness and vasculogenic mimicry). However, blockage of avb3 integrin in M14-N cells with neutralizing anti-integrin antibodies did not interfere with ECM cell invasion or vasculogenic mimicry, supporting the hypothesis that avb3 integrin contributes to the promotion of ECM invasion by melanoma cells only in the presence of VEGFR-2. On the other hand, the results obtained using blocking antibodies against avb5 integrin and silencing of b5 integrin chain indicated that the aggressive properties of M14-N cells depend not only on NRP-1 but also on this integrin. These data are in agreement with those described in a human fibrosarcoma model showing that the upregulation of NRP-1 is a critical event in the vasculogenic mimicry in vivo 40 and with the recent demonstration that avb5 integrin expression is strongly upregulated in brain metastases from malignant melanoma as compared to primary tumours. 41 Our results suggest a cross-talk between NRP-1 and avb5 integrin in M14-N cells that might derive from physical interactions between the two proteins or from NRP-1-dependent signal Cancer Cell Biology transduction pathways which favour avb5 integrin activation/ signalling. To this regard, in cross-linking and coimmunoprecipitation experiments we did not find any evidence of a direct physical interaction between NRP-1 and avb5 integrin in our model (data not shown). Conversely, since we have shown that the expression of NRP-1 in M14-N cells is sufficient to promote the activation of signal transduction pathways involving several protein kinases, 16 it is likely that these protein kinases may modulate avb5 integrin activity. Indeed, a number of data in the literature indicate that avb5 integrin can be regulated by protein kinases: (i) several avb5 integrin-mediated functions (such as cell spreading, colocalization of a-actinin, tensin, vinculin, p130Cas, actin and induction of FAK tyrosine phosphorylation) require PKC activation 42 ; (ii) the cross-talk between avb5 integrin and the epidermal growth factor receptor, implicated in the metastatic process of pancreatic carcinoma cells, involves signalling kinases such as Src and Rap-1 43 (iii) the role played by avb5 integrin in the vasculogenic mimicry of melanoma cells 27 is under the control of kinases, such as PKC, Akt, FAK or ERK. 44, 45 Interestingly, NRP-1 expression in melanoma cells promotes an increased secretion of MMP-2. 16 Since, it has been demonstrated that MMP-2 induces the activation of avb5 integrin, 30 this mechanism might also account for avb5 integrin triggering in NRP-1 positive melanoma cells.
Cilengitide, besides counteracting the adhesion of M14-N and M14C2/MK18 cells to vitronectin, markedly decreased their invasiveness and vasculogenic mimicry. In M14-N cells, the effects of this drug are due to the inhibition of avb5 integrin, given that similar results were obtained treating the cells with anti-avb5 integrin neutralizing antibodies and by silencing of the b5 integrin chain. Actually, cilengitide did not further decrease tubule-like structure formation in b5 silenced cells. Moreover, it downmodulated the release of VEGF-A and, also in this case, avb5 integrin inhibition is likely to be involved, as the activation of this integrin controls the PI3K-dependent production of VEGF-A by melanoma cells. 29 Accordingly, cilengitide has shown to inhibit phosphorylation of FAK, src and Akt in endothelial and glioma cells 28 and here we demonstrate that it downmodulates FAK phosphorylation in M14-N cells. Interestingly, in drugtreated cells also the chemotactic response to VEGF-A was strongly hampered, likely as a consequence of the modulation of FAK and/or other critical proteins involved in the response to VEGF-A and essential to the maintenance of an autocrine loop that promotes melanoma invasiveness. 14 Finally, cilengitide decreased MMP-9 secretion and activity, which were higher in M14-N cells than in control melanoma cells, suggesting an important role also for this MMP in the mechanism of action of the drug. The suggested mechanisms of action of cilengitide in NRP-1 expressing melanoma cells are summarized in Supporting information Figure S9 .
Noteworthy, the effect of cilengitide on melanoma aggressiveness was also confirmed using two nontransfected melanoma cell lines, originated from the same patient and representative of different malignant phenotypes: the WM115, characterised by high NRP-1 expression, high matrigel invasiveness, elevated capability to form tubule-like structures and low proliferation rate; the WM266-4, characterised by low NRP-1 expression, lower matrigel invasiveness, lower capability to form tubule-like structures and high proliferation rate. In fact, WM115 cells were significantly more susceptible than WM266-4 cells to the inhibitory effect of cilengitide on matrigel invasion and highly sensitive to the effect of the drug on vasculogenic mimicry.
Another important aspect of the studies herein presented is the possible clinical applications. Melanoma cells are able to elude the growth inhibitory effect of antiangiogenic therapies and quickly develop resistance to targeted therapies aimed at inhibiting constitutively activated kinases. 46 Thus, combination therapies including inhibitors of DNA repair, novel immunomodulators, targeted therapies or antiangiogenic agents are currently investigated to improve the outcome of melanoma patients. 47 Since vasculogenic mimicry is an alternative pathway to provide tumours with blood supply by an angiogenesis-independent mechanism, the ability of melanoma cells to produce vessel-like structures may contribute to resistance to antiangiogenic therapies and explain why these therapies have clinically failed in melanoma treatment. 48 Indeed, traditional antiangiogenic drugs have shown to be ineffective in hindering vasculogenic mimicry. 49, 50 Therefore, the combination of cilengitide with anti-VEGF-A agents is expected to be synergistic and to yield substantial antineoplastic effects.
In conclusion, the results herein presented identify specific av integrins that are involved in the aggressiveness of NRP-1-expressing melanoma cells: avb3 integrin, promoting ECM invasion in the presence of VEGFR-2; avb5 integrin, promoting cell adhesion to vitronectin and collaborating with NRP-1 in the development of an invasive and vasculogenic mimicry phenotype. Moreover, the involvement of avb5 integrin in the ability of highly aggressive melanomas to form vessel-like structures, provide the rationale for clinical testing of cilengitide in the treatment of metastatic melanoma.
